A detailed history of Handelsbanken Fonder Ab transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Handelsbanken Fonder Ab holds 20,000 shares of AKRO stock, worth $594,200. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,000
Previous 17,800 12.36%
Holding current value
$594,200
Previous $418,000 37.32%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 04, 2024

BUY
$21.45 - $29.34 $47,190 - $64,548
2,200 Added 12.36%
20,000 $574,000
Q2 2024

Aug 05, 2024

BUY
$18.31 - $24.62 $146,480 - $196,960
8,000 Added 81.63%
17,800 $418,000
Q4 2023

Feb 01, 2024

BUY
$11.38 - $50.33 $3,414 - $15,099
300 Added 3.16%
9,800 $229,000
Q2 2023

Aug 02, 2023

BUY
$36.89 - $56.88 $95,914 - $147,888
2,600 Added 37.68%
9,500 $444,000
Q4 2022

Feb 07, 2023

BUY
$33.44 - $54.8 $230,735 - $378,120
6,900 New
6,900 $378,000

Others Institutions Holding AKRO

About Akero Therapeutics, Inc.


  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $1.38B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Handelsbanken Fonder Ab Portfolio

Follow Handelsbanken Fonder Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

News

Stay updated on Handelsbanken Fonder Ab with notifications on news.